Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3BH1Y)

• Drug Name: Lapatinib Drug Info
• Synonyms: FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Gastroesophageal junction adenocarcinoma	2B71	Approved	[2]
Melanoma	2C30	Approved	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 208908
  ChEBI ID: CHEBI:49603
  CAS Number: CAS 231277-92-2
  TTD Drug ID: DM3BH1Y
  VARIDT Drug ID: DR00120
  INTEDE Drug ID: DR0917
  ACDINA Drug ID: D00351

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[16]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[17]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[18]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[19]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[20]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[21]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[22]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[23]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[24]
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[25]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[26]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[27]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[28]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[25]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[29]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[17]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[30]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[29]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[18]
Nitroglycerin	DMQ2491	Angina pectoris	BA40	Approved	[31]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[82]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[83]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[84]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[85]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[86]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[87]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[88]
Selenium	DM25CGV	N. A.	N. A.	Approved	[89]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[90]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[91]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[32]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[34]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[35]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[34]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[34]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[36]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[34]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[37]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[38]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[40]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[41]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[42]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[43]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[44]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[44]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[46]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[47]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[48]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[49]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[50]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[52]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[53]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[54]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[55]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[49]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[56]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[57]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[58]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[59]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[60]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[61]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[62]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[63]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[64]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[65]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[60]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[66]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[67]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[68]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[69]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[70]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[71]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[67]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[72]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[73]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[74]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[75]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[76]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[77]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[68]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[78]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[81]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[73]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[12]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[92]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[92]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[93]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[12]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[92]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[94]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[12]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[95]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[12]

Drug(s) Affected By Superoxide dismutase , mitochondrial (SOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Selenium	DM25CGV	N. A.	N. A.	Approved	[97]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[99]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[100]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[101]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[102]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[98]

Drug(s) Affected By Heme oxygenase 1 (HMOX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[105]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[106]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[107]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[108]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[109]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Selenium	DM25CGV	N. A.	N. A.	Approved	[110]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[111]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[112]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]

Drug(s) Affected By NAD(P)H dehydrogenase 1 (NQO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[114]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[115]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[116]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[117]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[118]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[119]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[120]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[121]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]

Drug(s) Affected By Nuclear factor erythroid 2-related factor 2 (NFE2L2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[123]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[108]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[87]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[117]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[125]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[120]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[127]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[102]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[128]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[129]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[130]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[131]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[132]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[133]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[134]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[137]

Drug(s) Affected By Estrogen receptor (ESR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[138]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[139]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[140]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[141]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[142]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[143]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[144]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[141]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[145]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[146]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[147]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[148]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[149]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[131]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[150]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[151]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[150]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[152]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[153]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[154]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[155]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[156]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[157]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[158]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[159]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[147]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[160]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[161]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[162]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[163]

Drug(s) Affected By DNA topoisomerase 1 (TOP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[159]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[164]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[165]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[166]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[167]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[168]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[169]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[114]

Drug(s) Affected By DNA topoisomerase 2-alpha (TOP2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[170]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[172]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[173]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[174]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[175]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[167]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[176]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[177]

Drug(s) Affected By Histone H2AX (H2AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[178]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[179]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[180]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[181]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[182]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[183]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[184]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[185]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[175]

Drug(s) Affected By Cyclin-A2 (CCNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[186]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[187]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[188]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[189]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[190]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[191]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[174]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[192]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[193]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[194]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[195]
Methysergide	DM1EF73	Migraine	8A80	Approved	[94]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[196]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[166]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[102]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[197]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[198]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[199]

Drug(s) Affected By Receptor tyrosine-protein kinase erbB-3 (ERBB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[200]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[201]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[202]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[203]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[204]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[205]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[206]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[207]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[208]

Drug(s) Affected By Alanine aminotransferase 1 (GPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[159]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[209]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[210]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[159]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[159]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[159]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[9]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[211]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[9]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[212]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[213]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[214]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[163]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[139]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[83]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[215]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[216]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[217]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[218]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[219]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[220]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[221]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[162]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[222]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[223]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[224]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[225]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[226]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[227]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[228]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[220]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[229]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[230]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[231]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[219]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[159]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[232]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[162]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[222]

Drug(s) Affected By RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[233]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[234]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[235]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[163]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[236]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[237]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[238]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[239]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[217]

Drug(s) Affected By DNA replication licensing factor MCM7 (MCM7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[240]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[241]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[175]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[242]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[243]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[243]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[203]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[244]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[245]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[246]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[247]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[248]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[249]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[250]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[251]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[252]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[253]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[254]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[255]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[83]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[256]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[257]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[258]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[259]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[193]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[260]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[261]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[262]

Drug(s) Affected By Caspase-7 (CASP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[263]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[87]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[264]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[265]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[266]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[266]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[267]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[268]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[269]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[270]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[271]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[147]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[161]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[272]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[273]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[131]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[274]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[275]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[276]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[155]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[254]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[147]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[160]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[277]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[272]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[215]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[278]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[279]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[151]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[280]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[189]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[281]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[282]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[283]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[284]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[285]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[286]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[287]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[107]

Drug(s) Affected By GTPase KRas (KRAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[288]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[289]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[290]
Tiazofurin	DM5JWV9	Solid tumour/cancer	2A00-2F9Z	Approved	[291]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[292]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[293]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[294]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[295]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[296]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[204]

Drug(s) Affected By HLA class II histocompatibility antigen, DQ alpha 1 chain (HLA-DQA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[297]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[298]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[202]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[295]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[299]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[300]
Capecitabine	DMTS85L	Adenocarcinoma	2D40	Approved	[301]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[302]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[297]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[303]

Drug(s) Affected By Zinc finger protein SNAI1 (SNAI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[200]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[304]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[305]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[306]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[307]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[308]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[309]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[310]
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[311]
Sanguinarine	DMDINFS	Dental plaque	DA08.4	Approved	[312]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[313]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[280]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[314]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[315]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[316]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[317]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[318]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[319]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[320]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[321]

Drug(s) Affected By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[322]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[203]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[323]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[324]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[325]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[326]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[327]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[328]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[329]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[102]

Drug(s) Affected By Transforming growth factor beta-1 proprotein (TGFB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[330]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[159]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[331]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[332]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[333]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[334]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[335]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[336]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[337]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[338]

Drug(s) Affected By Tenascin-X (TNXB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[339]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[166]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[290]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[340]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[208]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[165]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[341]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[342]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[343]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[344]

Drug(s) Affected By HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[345]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[346]
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[346]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[302]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[347]
Ticlopidine	DMO946V	Acute coronary syndrome	BA41	Approved	[348]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[346]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[307]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[290]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[3]
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Inhibitor	[3]
Eukaryotic elongation factor 2 kinase (eEF-2K)	TT1QFLA	EF2K_HUMAN	Inhibitor	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[5]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[8]
Cytochrome P450 3A5 (CYP3A5) Main DME	DEIBDNY	CP3A5_HUMAN	Substrate	[8]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Protein Interaction/Cellular Processes	[9]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[10]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[10]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[11]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[12]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[13]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[13]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Gene/Protein Processing	[13]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Gene/Protein Processing	[14]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Gene/Protein Processing	[15]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
• [2] Lapatinib FDA Label
• [3] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [4] Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
• [5] The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
• [6] Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
• [7] Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
• [8] Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
• [9] Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
• [10] Effects of lapatinib on cell proliferation and apoptosis in NB4 cells. Oncol Lett. 2018 Jan;15(1):235-242. doi: 10.3892/ol.2017.7342. Epub 2017 Nov 3.
• [11] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [12] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [13] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [14] CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
• [15] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [17] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [18] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [19] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [21] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [22] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [23] Clinical pipeline report, company report or official report of Roche (2009).
• [24] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [25] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [26] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [27] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [28] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [30] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [31] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [32] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [33] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [34] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [35] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [36] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [37] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [38] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [39] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [40] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [41] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [42] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [43] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [44] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [45] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [46] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [47] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [48] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [49] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [50] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [51] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [52] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [53] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [54] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [55] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [56] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [57] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [58] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [59] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [60] Drug Interactions Flockhart Table
• [61] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [62] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [63] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [64] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [65] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [66] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [67] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [68] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [69] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [70] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [71] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [72] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [73] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [74] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [75] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [76] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [77] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [78] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [79] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [80] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [81] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [82] Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
• [83] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [84] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [85] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [86] Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
• [87] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [88] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [89] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [90] Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
• [91] Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011 Mar;29(2):87-95. doi: 10.1002/cbf.1725. Epub 2011 Feb 9.
• [92] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [93] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [94] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [95] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [96] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [97] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [98] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [99] Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radic Biol Med. 2001 Jan 15;30(2):148-53.
• [100] Cissus quadrangularis ethanol extract upregulates superoxide dismutase, glutathione peroxidase and endothelial nitric oxide synthase expression in hydrogen peroxide-injured human ECV304 cells. J Ethnopharmacol. 2012 Sep 28;143(2):664-72.
• [101] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [102] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [103] Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
• [104] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [105] Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
• [106] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [107] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [108] Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
• [109] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [110] High selenium status in individuals exposed to arsenic through coal-burning in Shaanxi (PR of China) modulates antioxidant enzymes, heme oxygenase-1 and DNA damage. Clin Chim Acta. 2010 Sep 6;411(17-18):1312-8.
• [111] Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
• [112] Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 2008 Aug;20(2):379-84.
• [113] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [114] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [115] Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
• [116] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [117] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [118] Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
• [119] Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
• [120] Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
• [121] Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
• [122] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [123] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [124] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [125] Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016.
• [126] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [127] P21(Waf1/Cip1) plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem Toxicol. 2016 Feb;88:1-12. doi: 10.1016/j.fct.2015.12.004. Epub 2015 Dec 11.
• [128] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [129] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [130] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [131] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [132] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [133] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [134] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [135] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [136] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [137] CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology. 2006 Jun;50(8):1041-7. doi: 10.1016/j.neuropharm.2006.02.004. Epub 2006 Mar 30.
• [138] Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
• [139] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [140] Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
• [141] Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
• [142] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [143] Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
• [144] Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
• [145] Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
• [146] [Arsenic trioxide restores ER expression in ER-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice]. Zhonghua Zhong Liu Za Zhi. 2012 Sep;34(9):645-51. doi: 10.3760/cma.j.issn.0253-3766.2012.09.002.
• [147] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [148] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [149] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [150] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [151] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [152] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [153] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [154] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [155] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [156] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [157] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [158] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [159] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [160] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [161] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [162] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [163] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [164] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [165] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [166] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [167] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [168] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [169] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [170] Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res. 2001 Oct;92(10):1133-7. doi: 10.1111/j.1349-7006.2001.tb01069.x.
• [171] HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase II and . Chem Res Toxicol. 2018 Feb 19;31(2):137-144. doi: 10.1021/acs.chemrestox.7b00302. Epub 2018 Jan 8.
• [172] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [173] Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry. 2011 Apr 19;50(15):3240-9. doi: 10.1021/bi200094z. Epub 2011 Mar 28.
• [174] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [175] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [176] Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1552-6. doi: 10.1111/j.1525-1438.2006.00626.x.
• [177] Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor- by macrophages: role of the DNA damage response. J Pharmacol Exp Ther. 2014 Jul;350(1):164-70. doi: 10.1124/jpet.114.214189. Epub 2014 May 9.
• [178] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [179] Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
• [180] Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
• [181] Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
• [182] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [183] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [184] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [185] The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
• [186] Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
• [187] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [188] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [189] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [190] Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol. 2021 Mar 15;415:115450. doi: 10.1016/j.taap.2021.115450. Epub 2021 Feb 9.
• [191] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [192] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [193] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [194] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [195] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [196] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [197] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [198] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [199] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [200] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [201] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [202] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [203] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [204] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [205] Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
• [206] The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
• [207] Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. Cancer Prev Res (Phila). 2010 Apr;3(4):560-72. doi: 10.1158/1940-6207.CAPR-09-0159. Epub 2010 Mar 23.
• [208] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [209] Quercetin protected against isoniazide-induced HepG2 cell apoptosis by activating the SIRT1/ERK pathway. J Biochem Mol Toxicol. 2019 Sep;33(9):e22369. doi: 10.1002/jbt.22369. Epub 2019 Jul 23.
• [210] Drug-induced liver injury: Oltipraz and C2-ceramide intervene HNF-1/GSTA1 expression via JNK signaling pathway. J Appl Toxicol. 2021 Dec;41(12):2011-2020. doi: 10.1002/jat.4181. Epub 2021 May 6.
• [211] A Study of Gentianae Radix et Rhizoma Class Differences Based on Chemical Composition and Core Efficacy. Molecules. 2023 Oct 17;28(20):7132. doi: 10.3390/molecules28207132.
• [212] Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway. Toxicol In Vitro. 2016 Oct;36:186-196. doi: 10.1016/j.tiv.2016.07.017. Epub 2016 Jul 26.
• [213] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [214] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [215] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [216] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [217] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [218] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [219] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [220] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [221] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [222] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [223] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [224] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [225] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [226] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [227] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [228] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [229] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [230] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [231] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [232] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [233] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [234] Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer. 2010 Aug 20;9:220.
• [235] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [236] Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
• [237] Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
• [238] Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
• [239] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [240] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [241] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [242] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [243] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [244] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [245] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [246] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [247] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [248] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [249] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [250] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [251] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [252] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [253] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [254] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [255] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [256] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [257] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [258] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [259] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [260] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [261] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [262] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [263] Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021 Sep 7;13(9):1415. doi: 10.3390/pharmaceutics13091415.
• [264] A model to identify novel targets involved in oxidative stress-induced apoptosis in human lung epithelial cells by RNA interference. Toxicol In Vitro. 2010 Feb;24(1):310-8. doi: 10.1016/j.tiv.2009.08.008. Epub 2009 Aug 23.
• [265] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [266] Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
• [267] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [268] Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
• [269] Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
• [270] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [271] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [272] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [273] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [274] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [275] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [276] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [277] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [278] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [279] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [280] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [281] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [282] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [283] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [284] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [285] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [286] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [287] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [288] Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res. 1994 Jun;85(6):633-8. doi: 10.1111/j.1349-7006.1994.tb02406.x.
• [289] Quercetin and Its Fermented Extract as a Potential Inhibitor of Bisphenol A-Exposed HT-29 Colon Cancer Cells' Viability. Int J Mol Sci. 2023 Mar 15;24(6):5604. doi: 10.3390/ijms24065604.
• [290] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [291] Regulation of the signal transduction program by drugs. Adv Enzyme Regul. 1997;37:35-55. doi: 10.1016/s0065-2571(96)00025-8.
• [292] Hydroquinone-induced malignant transformation of TK6 cells by facilitating SIRT1-mediated p53 degradation and up-regulating KRAS. Toxicol Lett. 2016 Sep 30;259:133-142. doi: 10.1016/j.toxlet.2016.08.006. Epub 2016 Aug 8.
• [293] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [294] Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol. 2005 Sep;130(6):912-25. doi: 10.1111/j.1365-2141.2005.05696.x.
• [295] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [296] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [297] A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010 Aug;42(8):711-4. doi: 10.1038/ng.632. Epub 2010 Jul 18.
• [298] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [299] Glucocorticoid regulation of human eosinophil gene expression. J Steroid Biochem Mol Biol. 2003 Mar;84(4):441-52. doi: 10.1016/s0960-0760(03)00065-7.
• [300] Transcriptomics and methylomics of CD4-positive T cells in arsenic-exposed women. Arch Toxicol. 2017 May;91(5):2067-2078. doi: 10.1007/s00204-016-1879-4. Epub 2016 Nov 12.
• [301] Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoids. Toxicol Lett. 2022 Dec 1;371:17-24. doi: 10.1016/j.toxlet.2022.09.013. Epub 2022 Sep 29.
• [302] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [303] HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014 Oct;46(10):1131-4. doi: 10.1038/ng.3093. Epub 2014 Sep 14.
• [304] Manganese superoxide dismutase induces migration and invasion of tongue squamous cell carcinoma via H2O2-dependent Snail signaling. Free Radic Biol Med. 2012 Jul 1;53(1):44-50. doi: 10.1016/j.freeradbiomed.2012.04.031. Epub 2012 May 9.
• [305] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [306] Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-/Smad signaling pathways. Cell Biol Toxicol. 2021 Jun;37(3):479-496. doi: 10.1007/s10565-020-09562-0. Epub 2020 Oct 17.
• [307] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [308] Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Toxicol Sci. 2015 Jan;143(1):156-64. doi: 10.1093/toxsci/kfu218. Epub 2014 Oct 10.
• [309] In vitro antitumoral effects of the steroid ouabain on human thyroid papillary carcinoma cell lines. Environ Toxicol. 2021 Jul;36(7):1338-1348. doi: 10.1002/tox.23130. Epub 2021 Mar 24.
• [310] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [311] Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol. 2007 Sep;293(3):F723-31. doi: 10.1152/ajprenal.00480.2006. Epub 2007 Jun 27.
• [312] Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells. Chem Biol Interact. 2009 May 15;179(2-3):185-91. doi: 10.1016/j.cbi.2008.11.009. Epub 2008 Nov 21.
• [313] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [314] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [315] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [316] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [317] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [318] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [319] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [320] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [321] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [322] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [323] Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
• [324] Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
• [325] Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
• [326] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [327] Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
• [328] Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. doi: 10.1124/jpet.105.086504. Epub 2005 Apr 21.
• [329] Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
• [330] Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
• [331] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [332] Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 2010 Feb 15;70(4):1314-22. doi: 10.1158/0008-5472.CAN-09-3292. Epub 2010 Feb 9.
• [333] PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal. 2002 Dec;4(6):877-84. doi: 10.1089/152308602762197416.
• [334] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [335] Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol. 2003 Apr;90(4):452-5. doi: 10.1016/S1081-1206(10)61832-7.
• [336] Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 2009 Jun;157(3):362-70. doi: 10.1111/j.1476-5381.2009.00161.x. Epub 2009 Apr 9.
• [337] Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
• [338] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [339] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [340] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [341] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [342] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [343] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [344] Pregnancy exposure to synthetic phenols and placental DNA methylation - An epigenome-wide association study in male infants from the EDEN cohort. Environ Pollut. 2021 Dec 1;290:118024. doi: 10.1016/j.envpol.2021.118024. Epub 2021 Aug 21.
• [345] The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005 Mar;35(3):339-44. doi: 10.1111/j.1365-2222.2004.02197.x.
• [346] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [347] A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
• [348] Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6.